Eisai and Biogen Present Preliminary Assessment of the Clinical Effects of Lecanemab Following 18 Months of Treatment in the Open-Label Extension of the Phase 2 Proof of Concept Study at 2021 ...
Lecanemab is an investigational humanized monoclonal antibody that preferentially binds to soluble amyloid-beta (Aß) aggregates (protofibrils). Lecanemab reduced brain Aß and slowed clinical decline ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback